The IgM paraprotein secretion is most frequently associated with Waldenström's macroglobulinemia. In very rare cases it may also occur in multiple myeloma. The diagnostic and therapeutic process of a 84 year old male suffering from IgM multiple myeloma is described, including difficulties in establishing this diagnosis. Due to infectious complications, after the first cycle of melphalanprednisone-bortezomib treatment, melphalan was stopped, subsequently, bortezomib and prednisone doses were also reduced. Two treatment interruptions have occurred. Despite reduced treatment intensity, the patient was in very good partial remission, while the toxicity profile was acceptable.
INTRODUCTION
Multiple myeloma is a plasmocyte dyscrasia with an incidence of 5.8/100,000/year [1] . Clonal cells usually retain the ability to produce immunoglobulin -most often IgG (52%) or IgA (21%) class, less frequently IgD (2%) or IgE (<0.01%), while cases of IgM multiple myeloma are scarce [2] . Detection of the IgM paraprotein itself is not that rare. Its presence is associated with Waldenström's macroglobulinemia -lymphoma deriving from a transformed cell being in an intermediate stage between lymphocyte B and plasmocyte (incidence of 3/1mln/year) [3] . The decision as to the diagnosis of IgM multiple myeloma or Waldenström's macroglobulinemia is not only theoretic. They are distinct nosological entities with different prognosis, complications and, most importantly, different optimal treatments [4] .
The aim of this work is to present the diagnostic and therapeutic process of a patient with IgM multiple myeloma, including the difficulties in establishing this diagnosis.
CASE DESCRIPTION
An eighty four year old man presented in June 2013 to the Department of Hematology, Oncology and Internal Diseases with a suspicion of myelodysplastic syndrome (WBC 4,3 G/l, Hb 11,0 g/dl, PLT 87 G/l) with increasing fatigue and dyspnea.
He had a long history of heart disease (chronic heart failure NYHA II, implantation of mechanical aortic valve in 2000, chronic atrial flutter, chronic anticoagulation with acenocumarol), and additionally: stage 3 of chronic kidney disease, cholelithiasis and knee joint pain. Despite the age and above-mentioned history, the patient was in fairly good clinical condition (ECOG 1, Karnofsky 80%). There were no signs of hyperviscosity syndrome. Hyperproteinemia (total protein 11.8 g/dl) and peak of monoclonal protein (5.07 g/dl) detected in serum protein electrophoresis suggested that the cause of cytopenia was not MDS, but rather multiple myeloma infiltration. When the paraprotein was typed as IgM kappa with kappa free light chains (IgM concentration of 7896 mg/dl), Waldenström's macroglobulinemia seemed to be more probable. This diagnosis was additionally supported by the lack of osteolytic lesions in a bone X-ray. 162 A buted to the β-adrenolytic and digoxin treatment, which were subsequently discontinued. After 2 administrations of bortezomib and a break that followed, when there was no recurrence of arrhythmia, the previous regimen was continued. In further observation, no 3 rd degree atrioventricular block appeared.
Due to the increasing psychological abnormalities (deterioration of the logical contact, agitation, delusional thoughts) which were attributed to the glucocorticoid use (steroid psychosis) from the fifth cycle, prednisone dose was reduced from 100 to 50 mg daily.
As the symptoms permanently receded, the dose was increased to 60 mg, with good tolerance thereafter.
After the first part of the first cycle of treatment, partial remis- After the eighth cycle (12 months from the beginning of the therapy), the patient's condition rapidly deteriorated while he was at home. He was admitted to a nearby hospital with severe pneumonia complicated with ARDS and pulmonary edema. The family informed the attending treating physician about the patient's death by telephone. During the last 3 months no neutropenia (ANC 3.7 G/l at the last bortezomib administration) occurred, and the IgG concentration was only slightly decreased and remained above 500 mg/dl.
DISCUSSION
We describe probably the first Polish case of an elderly patient suffering from IgM multiple myeloma who was treated with bortezomib for one year. This therapy became available in Febru- The treatment resulted in a good response with an acceptable toxicity profile. For an elderly patient, controlling the disease course is more important than taking the great risk of getting life-threatening complications, even if to achieve a long-lasting remission. In the described patient, despite the gradual reduction in treatment intensity (melphalan discontinuation, bortezomib and, subsequently, steroid reduction), that goal was achieved.
Two interruptions in the treatment occurred. During the first one, paraprotein concentration increased, while the second one did not have such an effect. Despite these limitations in the treatment intensity, the patient achieved VGPR (very good partial remission), and there was no increase in the disease symptoms (renal insufficiency, anemia).
Reports of bortezomib treatment in IgM multiple myeloma are scarce. Japanese patients with IgM multiple myeloma and advanced amyloidosis had a good response to bortezomib as a second--line treatment [5] . Two patients in Austria had a good response to bortezomib with dexamethasone [6] . Three out of four Chinese patients received bortezomib in induction therapy and had a PFS of only 6.0 (2.5-7.0) months with an OS of 17.5 (2.5-27), despite a younger age than the described patient (54-69 years) [7] . Interestingly, three of them had a 11:14 translocation. also be considered [8] .
Some investigators use the presence of 11:14 translocation as a diagnostic criterion, as it was frequently found in this multiple myeloma type (5/8 patients [9] ; 7/8 patients, while absent in 17
Waldenström's macroglobulinemia patients [4] ). This cytogenetic aberration is frequently associated with cyclin D1 overexpression [9, 10] . It was found in 15-24% of multiple myeloma patients [10] and is associated with a low cytogenetic risk [1] . The described patient did not have translocation 11:14, but immunohistochemical staining for cyclin D1 was positive, which may suggest that a mutation with similar effect occurred but was not associated with karyotype alterations. This patient's case does not support the necessity of t11:14 and/or osteolytic lesions presence for IgM multiple myeloma diagnosis [4] .
On patient's cells CD20, CD56 and CD117 antigens were not expressed, which was described as characteristic for IgM multiple myeloma [9] .
In the largest IgM multiple myeloma group, the mean survival of 30 months was similar to the prognosis for other types at that time [4] . It is worth mentioning that the patients were much younger (55-77 years) and often the disease was less advanced.
This patient survived for 12 months from the diagnosis and died from severe infection, concordant with the observed high proportion of early deaths caused by sepsis in this patient group [9] .
An unusual situation is the impossibility of classifying the di- IgM multiple myeloma should be included in the differential diagnosis of IgM paraproteinemia, also when osteolytic lesions and translocation 11:14 are not detected. Bortezomib-based therapy can be effective in elderly patients (also in those suffering from cardiac insufficiency), even when dose reduction is required.
